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 ABSTRACT 
Fatigue is a common complaint and considered a very challenging symptom to cope 
with in many different medical diseases. The assessment of fatigue is bound up with 
the problems of both conceptualization and definition. In addition, few studies have 
investigated suitable neuropsychological tests to examine fatigue and its 
consequences. 
This thesis evaluates whether neuropsychological tests can elicit cognitive fatigue. It 
also investigates whether specific hormones and hormone replacement therapy 
influence fatigue as well as cognitive performance.  
Study I examined and compared neuropsychological measures of cognitive fatigue 
with self-rated fatigue in patients with mild traumatic brain injury (mTBI). These 
patients scored significantly higher than controls on both self-rated and on test-
derived measures of cognitive fatigue. Cognitive fatigue was best captured with a 
score derived from the WAIS Digit Symbol. From our findings we concluded that 
cognitive fatigue was independent of depression and sleep disorder. Self-rated 
fatigue, on the other hand, was highly correlated to depression. 
Study II compared the effect of combined testosterone and estrogen replacement with 
estrogen treatment alone on subjective and objective measures of memory in 
oophorectomized women. Treatment with testosterone undecanoate 40 mg and 
estradiol 2 mg was associated with lower performance on immediate verbal memory 
compared to treatment with estrogen plus placebo. All other memory functions were 
unaffected. 
Study III explored cognitive fatigue in oophorectomized women, and whether 
hormonal treatment regimens, as described in study II, were related to self perceived 
well-being, estrogen or testosterone serum levels. We found that cognitive fatigue 
was frequent in oophorectomized women and negatively associated to self-perceived 
health and positively associated to BMI. However, treatment with testosterone + 
estrogen or estrogen alone had no significant effect on cognitive fatigue.  
 
Study IV investigated fatigue and cognitive performance in patients with Graves’ 
disease (GD). As compared to controls, patients with GD scored significantly higher 
on self-rated fatigue and had a higher frequency on the cognitive fatigue. They also 
demonstrated lower performance on learning, memory, and various tests of executive 
functioning. Depression was associated with self-rated fatigue but not with the 
cognitive fatigue measure. High-free triiodothyronine (T3) levels were positively 
associated to better cognitive functions but negatively to self-rated everyday 
consequences of fatigue among the patients.  
 
In conclusion: Cognitive fatigue measure, derived from Digit Symbol, could be a 
useful instrument to capture fatigue. It enables us to calculate an index of cognitive 
fatigue where neither depression nor sleep disturbance interfere with the result. 
Cognitive fatigue seems to be related to BMI and self-rated health but not directly 
related to hormonal levels. A curvilinear relation to sex hormones and the 
estrogen/testosterone ratio seem more likely. Indirect hormonal imbalances could 
influence subtle neuronal mechanisms leading to discrete neuropsychological 
dysfunctions.  
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1 INTRODUCTION 
1.1 FATIGUE 
Fatigue is a frequent and challenging presenting symptom for a wide range of medical 
conditions, including neurological conditions 1-3, traumatic brain injuries 4-8 stroke 9-11, 
and  psychiatric disturbances 12,13. Complaints of fatigue have also been documented in 
cases in which hormonal changes are associated with menopause 14 and 
hyperthyroidism 15-17. However, fatigue is not restricted to medical diagnoses – as it is 
common also in the general population 18.  
 
Fatigue is associated with reduced social and physical functioning 19,20 and an important 
predictor of failure to return to work after sickness leave 21. The prevalence of 
depression is however high among patients with neurological disorders 22 and as fatigue 
is a common complaint in depressive disorders, it is an open question if there are shared 
underlying mechanisms of fatigue between different, e.g. depression and medical, 
disorders 12.  
 
Although fatigue is such a common symptom the assessment of fatigue is still bound up 
with the problems of both conceptualization and definition 23-25. Suitable clinical 
applicable neuropsychological tests to measure fatigue are lacking 26.   
 
It is, therefore, of interest among clinical neuropsychologists to identify methods to 
capture fatigue and in order to investigate its relationship with other states, such as 
depression, sleep disturbances and hormonal changes.  
 
 
1.1.1 Definitions of fatigue 
Fatigue is a multidimensional concept involving both physiological and psychological 
aspects. The experience of fatigue is subjective 27and can be described in physical, 
cognitive, and emotional dimensions. Common symptoms described in literature 12,28,29 
are presented in Table 1.  
 
 
Table 1. Different dimensions of fatigue and examples of descriptions   
Physical Cognitive Emotional 
-  Loss of voluntary force- 
producing capacity 
 - Low/lack of energy 
 - Tiredness 
 - Decreased endurance 
 - Increased effort with 
physical tasks 
 - General weakness  
 - Heaviness 
 - Slowness  
 - Sluggishness 
 - Non-restorative sleep 
 - Sleepiness 
- Decreased concentration 
 - Decreases attention 
 - Decreased mental 
endurance 
  - Slowed thinking 
 - Decrease/lack of 
motivation 
 - Decrease/lack of 
initiative 
 - Decreased interest 
 - Feeling overwhelmed 
 - Feeling bored 
 - Aversion to effort 
  - Feeling low 
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In physiology, fatigue is usually defined as “loss of voluntary force-producing 
capacity during exercise” (Zwarts et al., 2008, page 3) and its origin can both be 
central or peripheral 29. Peripheral fatigue or muscle fatigability is more easily defined 
and involves the peripheral nervous system, motor neurons and neuromuscular 
junctions 1,30,31, while the subjective sense of fatigue is fundamentally perceived in the 
central nervous system (CNS), which makes it more complex 1,29,31. The subjective 
experience of fatigue may be concomitant with physiological fatigue or with 
deteriorating performance, but may also be a sole complaint 6,23,29,32,33. For example, 
some post-polio survivors differentiate between physical fatigue due to muscle 
weakness and a “brain fatigue” related to cognition problems 34.  
 
Zwarts et al. 29 separate physiological fatigue from psychological fatigue. The former 
includes both peripheral and central fatigue, while psychological fatigue refers to the 
subjective experience of fatigue, including concerns about impaired ability to 
concentrate, lowering of daily functioning, making attributions about fatigue, changes 
in social functioning and diminished psychological well-being. These are considered 
best measured with questionnaires 29.  
 
Mental fatigue is a concept found in the literature on fatigue that Ashman (2008, page 
34) described as a result from “an imbalance between the amount of mental effort or 
activity required to perform a task and the internal resources that person has available 
to perform it”. The mechanisms contributing to insufficient resources are, however, 
likely to be multi-dimensional 33. Some years ago the concept of cognitive fatigue was 
introduced and is associated with decrements in cognitive performance 32,35. In this 
thesis, mental fatigue is a general concept including motivational, cognitive and 
subjective fatigue; cognitive fatigue is fatigue that can be measured as performance 
decrements over time of sustained mental effort 36; and subjective fatigue is considered 
the inner experience of fatigue measured with self-rating instruments 29. This thesis will 
focus on different aspects of cognitive fatigue.  
 
 
1.1.2 Neural correlates 
The basal ganglia are considered exquisitely vulnerable to neurodegenerative 
processes such as injuries due to hypoxia, invasion of viruses and pro-inflammatory 
cytokines. Also, many neurological diseases involve these structures. Parkinson 
disease, multiple sclerosis (MS), and chronic fatigue syndrome include fatigue as a 
common and disabling symptom. Therefore, these structures could be related to 
fatigue 37. Possible mechanisms behind fatigue’s involvement with the basal ganglia 
include interrupted connectivity between the prefrontal cortex and thalamus, but also 
potential disturbances in limbic integration of cortically driven, voluntary activities 1. 
Fatigue related symptoms reported by post-polio patients led Bruno et al. 34 to propose 
that fatigue results from viral damage to the reticular formation, hypothalamic and 
thalamic nuclei, cortical motor areas, and dopaminergic neurons in the basal ganglia. 
Injuries in these regions could lead to decreased cortical activation, impaired attention 
and slowing of processing speed, which consequently generate the feeling of fatigue 34. 
Few studies have, however, found associations between self-rated fatigue and lesion 
load 31. Pellicano et al. 38 found that the posterior parietal cortex was the only area 
significantly associated self-rated fatigue in MS patients. Some functional MRI (fMRI) 
studies have found higher self rated fatigue among patients with hypometabolism in 
frontal regions and the basal ganglia 31,39,40. In stroke patients self-rated fatigue has 
mostly been related to the state of mood at the time of assessment 41 but some studies 
have found a relationship between an increased risk for post-stroke fatigue and 
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infratentorial infarctions 42 and infarctions in basal ganglia 43. One other study 
identified a gradient for complaints of fatigue, noting their low frequency in cortical 
lesions, intermediate frequency in thalamic lesions, and high frequency in brainstem 
lesions 44. 
 
Results are inconclusive  about the association between severity of injury and fatigue in 
traumatic brain injury (TBI) 4,45,46 However, a prospective longitudinal study found that 
those patients with significant increases in subjective fatigue over a 2-year period 
demonstrated poorer outcomes compared to those with decreased or stable fatigue 47. In 
a small imaging study on non-depressed mild traumatic brain injury (mTBI) patients 
with persisting fatigue at least 6 months from injury, Hattory et al. 48 found that mTBI 
patients demonstrated a different pattern of activation while performing the Paced 
Auditory Serial Addition Test compared to healthy controls. The authors concluded that 
frontocerebellar dissociation may explain cognitive fatigue in the chronic recovery phase 
of mTBI 48. 
 
 
1.1.3 Comorbid factors  
In disorders affecting the CNS investigators are unlikely to identify a single 
explanatory mechanism for fatigue 4,28. Fatigue may arise from a primary disease 
process due to dysfunctions in certain brain areas or from secondary processes due to 
e.g. medication, depression and sleep disturbance 31,39.  
 
1.1.3.1 Sleep disorders  
Various kinds of sleep disturbances give rise to self-rated fatigue 49; and pain, 
depression, restless legs syndrome, and medication effects contribute to sleep 
disturbances 50. These symptoms are commonly experienced in patients with diseases 
affecting the CNS. From a sample of 452 TBI patients Ouellet and Morin (2006) found 
that 50.2% reported insomnia symptoms and 29.4% fulfilled the diagnostic criteria for 
an insomnia syndrome, which was three times greater than reported in the general 
population 4.  
 
Sleep disturbances may also be accompanied by performance decrement. A meta 
analytic study showed that mood seems most affected by partial sleep deprivation 
followed by cognition, while motor performance seems to be most robust in conditions 
of disturbed sleep 51. Vigilance, measured by the frequency and duration of lapses, is 
also negatively affected by disturbed sleep 52. 
 
1.1.3.2 Depression  
The prevalence of depression is high among patients with medical or neurological 
disorders, which can influence symptom ratings 53 , though symptoms that are 
associated with neurological disease might also mimic those of depression 22,54.  
 
Results are inconsistent showing an association between depression and cognitive 
impairment, and not all individuals with major depression show cognitive deficits. 
Discrepancies among results may be due to factors such as population characteristics 
(e.g. degree or subtype of depression, age, and comorbid illnesses) or differences in 
test properties. Cognitive deficits are however frequently observed among depressed 
on tasks requiring attention, mental flexibility/control, visual-spatial abilities, visual 
scanning/visuo-motor tracking, executive functions such as verbal fluency (especially 
phonemic fluency), and verbal and nonverbal learning and retention 55,56. 
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Depression is a contributing factor to self-rated fatigue 57,58 and in cases of patients 
suffering from diseases affecting CNS there can be overlap in symptomatology 
between fatigue and depression making it difficult to disentangle the comorbidity 
between depressive syndromes and fatigue syndromes. Fatigue may develop in 
connection with activities demanding sustained effort, or be present independently as 
a state close to a lack of initiative. When fatigue is associated with loss of interest, it 
might be more related to a depressive state 44, which also includes lack of self-esteem, 
despair, or feeling of hopelessness. These feelings are not prominent in fatigue not 
related to depression. The ability to distinguish depression from fatigue is, however, 
complicated by the fact that atypical depression is more difficult to detect and fatigue is 
significantly more reported among patients with atypical depression compared to other 
depressed groups 12.  
 
1.1.3.3 Medication 
Medications affecting the CNS can modulate both cognition and subjective ratings of 
fatigue. A number of medical conditions as well as their medications, including 
antihistamines, antibiotics, beta-blockers, and medications for high blood pressure, 
have been associated to reports of fatigue 29,59 but evaluation of cognitive effects is not 
easily achieved due for example, to a lack of test sensitivity, practice effects with 
repeated neuropsychological assessments, and other confounding factors 60. Moreover, 
subjective reports of fatigue need not be consistent with objective measures. In a small 
treatment study on the neuropsychological effects of beta-blockers on 35 hypertensive 
patients, beta-blocker treatment was not associated poorer neuropsychological 
functioning; and, although these patients made substantial complaints of fatigue, 
complaints were equivalent in beta-blocker and placebo conditions 61. In a study of 
MS patients, those patients with medication that was considered to contribute to CNS 
effects demonstrated lower performance on tests of processing speed, attention and self 
rated fatigue; however, no causal relation could be drawn from this study 62. Opioids 
have also been associated with fatigue. In a double-blind study by Allen et al. 63 on 
healthy, male college students administered a combination of opioid (7.5 mg 
hydrocodone bitartrate) plus ibuprofen (200 mg) performed significantly less well on 
a simple tracking task and made significantly more errors on a simple reaction-time 
task than subjects using ibuprofen alone or a placebo. However, the deficits were 
highly transitory and did not correlate with confusion or fatigue 63. Antidepressant 
therapies have been associated with both physical and cognitive side effects 56. Fava et 
al. 64 studied patients who were treated using antidepressant medication during partial 
or full remission from depression and they reported more than 30% of exhibited 
cognitive symptoms (all responders to antidepressants). Physical symptoms of fatigue 
and sleepiness/sedation were reported by over 40%64. These were, however, self-
reported symptoms, and no neuropsychological assessments were performed, and no 
control group was used for comparison. Further, questions regarding fatigue were not 
included in the instrument used for evaluation of remission from depression 65; 
therefore, some of the fatigue symptoms could have been due to incomplete resolution 
of depressive symptoms.  
 
1.1.3.4 Gender 
Generally 49 but also specifically in stroke 9 and trauma 57 populations gender predicts 
women are more likely to self-rate greater fatigue. Women also seem to be at a greater 
risk for developing fatigue in depression, especially in the atypical-depressed group 
there seems to be a significantly higher percentage of women. The reasons for this sex 
difference are not known but atypical depression might be associated with endocrine 
abnormalities that differ from the classic melancholic depression 12. 
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1.1.4 Fatigue a symptom or a dysfunction? 
Fatigue can, to some extent, be objectively measured by quantifying performance over 
time, but this does not capture the subjective experience of fatigue. Research has shown 
little to no relationship between self-reported fatigue and neuropsychological 
performance in a variety of clinical populations. When self-rating instruments are used, 
other inner states such as depression, are highly connected with the results. For 
example, depressed patients tend to score higher than non-depressed patients on 
generally all symptom rating measures 66. When assessing patients with mild brain 
dysfunction, neuropsychological instruments may lack sensitivity to detect cognitive 
fatigue, while other psychological reactions, such as anxiety and depression, might 
account for results on the self-rating measures. 
 
Leavitt and DeLuca (2010) argue that instead of striving for associations between 
subjective and objective measures of fatigue, future research needs to separate primary 
fatigue, that is, the factors that initiate fatigue (e.g., systemic disease), from secondary 
fatigue, which are factors that perpetuate or exacerbate it (e.g., sleep disturbances and 
depression). Making this distinction would take better account of the multidimensional 
features of fatigue 67. 
 
The investigation of fatigue becomes further entangled by the lack of 
neuropsychological instruments that can capture fatigue. In cases that incorporate 
diffuse symptoms, such as fatigue, symptoms may, unwittingly, be attributed to 
psychiatric disorders. As self-rating instruments are influenced by depression these 
instruments have limitations in purposes of measuring primary fatigue. Therefore, it 
may not be sufficient to recognize that the patient suffers from fatigue just on the basis 
of a questionnaire. To be able to capture fatigue and also to be able to evaluate 
treatment effects it may therefore be worthwhile to find additional methods, not 
influenced by depression or sleep disorders 1.  
 
1.1.4.1 Neuropsychological findings and fatigue 
In most studies questionnaires measures of fatigue are compared to indices of 
neuropsychological performance, searching for any association between subjective 
fatigue and neuropsychological impairment. Few studies have been designed to 
investigate cognitive performance decline over time as a measure of fatigue.  
 
In studies on TBI patients, subjective fatigue has mainly been associated with 
decreased performance on measures of sustained or dual attention and reduced 
processing speed 6,33,68-70. In a study, Ziino and Ponsford 71 reported associations 
between self-reported fatigue on the Fatigue Severity Scale (FSS) and lower 
performance on a task of higher order attention 71. In another study, the same group 
found a relationship between self-rated fatigue on visual analog scale of fatigue and a 
greater number of omission errors on a vigilance task. A subgroup of TBI patients also 
showed performance decline on a vigilance task and along with a disproportionate 
increase in subjective fatigue72. Ashman and collaborators 33 assessed the relationship 
between performance and both situational and day-to-day fatigue in their study on TBI 
patients. In addition, the study examined the relationship between objectively measured 
fatigue and self-reported situational and day-to-day fatigue. Patients with diagnosed 
TBI scored significantly higher than controls on the fatigue measures and higher 
subjective day-to-day fatigue scores were associated with slower performance speed at 
the end of the tests. The TBI patients also showed significant decline in performance 
accuracy. This was, however, not associated with subjective fatigue 33. Fatigue in TBI 
 6 
has also been associated to day-time sleepiness and reduced alertness, as well as to 
poorer performance on tests assessing driving capacity 73. 
 
A robust measure of cognitive fatigue, which supports a model of decreased 
performance over time, employs tasks demanding sustained mental effort 26. In a study 
by Chapelle and Finlayson (1989) on brain injury patients with variable etiology 
(trauma, stroke or encephalitis), fatigue was operationalized as the inability to sustain 
the speed of finger tapping. On this simple task no group differences emerged between 
patients and healthy controls 74, while in a study of TBI patients with mixed severity, 
Melamed et al (1985) found, in a task demanding divided attention, that patients made 
more errors at the end of the test, suggesting that fatigue was a factor in decreased 
performance 75.  
 
Studies on cognitive fatigue after mTBI are lacking. Most studies have included 
patients with TBI of mixed severity levels. In one of the few studies performed on 
fatigue and mTBI, Cicerone (1996) used a modified version of Ruff 2 & 7 Selective 
Attention Test (Ruff 2 & 7 SAT) as a measure of fatigue. Cicerone found each mTBI 
and control group displayed lower processing speed over time but the mTBI patients 
did so to a significantly greater extent when they were challenged to perform another 
task simultaneously. This discrepancy between patients and controls was not found 
when the patients were exposed to irrelevant stimuli while performing. These findings 
indicate subtle cognitive deficits in mTBI patients may become apparent under 
conditions that require highly demanding, controlled cognitive processing 68.  
 
Individuals suffering from post TBI fatigue often describe thinking as effortful and 
ineffective 33 , though performance is not necessarily lowered when the subject 
experiences the test as effortful. Ziino and Ponsford 72 reported finding that TBI 
patients generally performed at a lower but at a similar level across the duration of a 
vigilance test compared to the controls However, the TBI patients showed greater 
elevation in diastolic blood pressure, which was associated with greater increase in 
subjective fatigue ratings. This could indicate that some patients are able to compensate 
for cognitive task demand but at the cost of increased stress 72. The theory of 
compensatory mechanisms received some support from an imaging study by 
McAllister et al. on mTBI patients. They did not obtain significant findings of 
performance differences between mTBI patients and healthy controls when performing 
working memory tasks. However, mTBI patients needed greater activation of neural 
networks 76. 
 
 
1.1.5 Operationalization of cognitive fatigue  
Operational definitions of the construct of fatigue run the risk of confusion owing to 
several factors, including: many different types of fatigue, the many multifaceted 
mechanisms behind different types of fatigue, relative lack of previous robust 
operational definitions, and lack of instruments capable of capturing often subtle 
cognitive effects of fatigue. This underscores the need to describe different aspects of 
fatigue when comparing studies 26,33. 
 
As noted above, theoretically, cognitive fatigue is defined as performance 
deteriorations over time. It has also been proposed in the literature that tasks used to 
investigate performance should demand sustained mental effort in order to provoke 
fatigue-related deficits 26,32,77. Task that demand processing of novel or inconsistent 
information 32 or sustained attention 26,37 have been proposed to be more likely to show 
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fatigue-related decrements. Despite this, few studies have been reported that explore 
which existing neuropsychological tests have appropriate test characteristics to capture 
cognitive fatigue in clinical populations. Furthermore, little is known about underlying 
components, including executive or motor functioning, which are necessary to assess in 
order to identify fatigue in mild and diffuse brain dysfunctions. 
 
Edith Kaplan defined fatigue as an inability to maintain consistent speed of 
performance over the period of the test 78 and she advocated that using the subtest Digit 
Symbol from Wechsler Adult Intelligence Scale (WAIS) to measure fatigue in clinical 
settings. The Digit Symbol Test (DST) demands interaction of cognitive fatigue, 
psychomotor speed and incidental learning capacity - functions that are vulnerable to 
different brain influences 69,70. Generally, performance quickens toward the end of the 
test as learning of digits normally occurs. If performance speed does not improve over 
time, the reason could be an inability to maintain a stable performance over time or to a 
low learning capacity 79. Therefore, the DST is suitable as at least a partial measure of 
complex psychomotor aspects of cognitive fatigue. Similarly,– the Symbol Digit 
Modalities Test, has been used to capture fatigue in patients with mTBI 77,  and a 
modified version has been used in an fMRI study on central fatigue in MS patients 40. 
Still, the DST, as a fatigue measure, has not been widely used in fatigue research and 
comparisons with other tests have not been made that lead to finding suitable tests to 
measure fatigue among patients with mild cognitive dysfunction.  
 
Speed and executive functioning are useful qualities for detecting cognitive fatigue. 
Inhibition and working memory are both examples of executive functions. It is, 
however, not clear if working memory exclusively is important when measuring 
cognitive fatigue. The Stroop Color-Word Test is a speed and accuracy test that taps 
inhibition but not working memory. If working memory is not important for fatigue-
related performance decrement this test might also have properties that tap executive 
aspects of cognitive fatigue.  
 
Complex attention factors have been associated to fatigue 35,71. To investigate if fatigue 
could be tapped by pure attention tests, the Ruff 2 & 7 Selective Attention Test could 
be used as a measure of attentional aspects of cognitive fatigue. The Ruff 2 & 7 SAT 
has been used in research on fatigue, but with a non-standardized procedure 68. The test 
is purported to measure both simple and controlled perceptual functions. It demands 
speed but does not carry a large demand for motor functioning or for working memory 
80. Theoretically, the Ruff 2 & 7 SAT- controlled search speed measure should be more 
vulnerable to fatigue effect over time compared to functions related more to automated 
attention measured by the Ruff 2 & 7 SAT - attention detection speed measure. Also 
the Ruff 2 & 7 SAT permits intermediate performance registrations. 
 
By matching different tests with different fatigue-related properties a battery of suitable 
tests for assessing fatigue could be developed (Figure 1). 
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Figure 1. Possible underlying components comprising the different fatigue measures. 
Italics highlight the specific features of the tests. 
 
 
1.2 HORMONES AND COGNITIVE FUNCTIONS  
Hormones are signaling molecules, released by a cell or a gland to the bloodstream, 
with a specific regulatory effect on the activity of a distant tissues and organs, where 
they can bind to specific receptors - acting as the postmen of endocrine machinery 81.  
 
 
1.2.1 Sex steroid hormones 
Sex steroid hormones affect not only sexual functions but also mood, behavior and 
cognitive functions 82-84. They are synthesized from cholesterol by enzymatic cleavage 
into precursors for estrogen and testosterone (Figure 2) and act on a genomic level 
through specific nuclear receptors to regulate the transcription of specific genes. 
However, these also act via non genomic action involving membrane-associated 
receptors 85-88. Therefore, sex steroid hormones can have both organizational effects 
engendering permanent structural change but also demonstrate rapid activating effects 
on the tissue. The organizational effects are most critical during specific periods of 
development while the activating effects are considered to be relatively transient 83,89. 
 
A small amount of these steroids are synthesized in the CNS and their activity is 
mediated by various neurotransmitters 88.  
 
Sex hormone receptors in the CNS are widely distributed but are mainly found in the 
hypothalamic and limbic areas 82. Postmortem examination of female brains show that 
the highest concentrations of estradiol and testosterone are in the hypothalamus, 
preoptic area and substantia nigra 90. Very few studies have however been able to find 
correlation between the concentration of steroid receptors in a particular brain area 
and behavior 91. 
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Figure 2. Schematic view of sex steroid hormone synthesized from cholesterol. 
 
Testosterone and estrogens are considered to be potentially neuroprotective hormones 
83,92-95. However, studies investigating associations between sex steroid levels and 
human cognition have shown inconclusive results 46,96-99. Some studies indicate that the 
association between neuropsychological function and sex steroid levels might not be a 
straightforward dose dependent one, rather, a curvilinear model is more plausible for 
cognitive functions 100,101. Also the balance between estrogen and testosterone, and thus 
the estradiol/testosterone ratio, has been suggested to be more important than the 
absolute hormone levels 102. 
 
1.2.1.1 Estrogen 
Estrogen consists principally of three forms: 17β-estradiol, estrone, and estriol. 
Estrogen receptors (ER) are recognized in brain regions such as the hippocampus, 
cerebral cortex, hypothalamus, and brainstem 82,85,103,104.  
 
Of the estrogen produced, 90 % is generated in the ovaries; but brain-derived estrogen 
also seems to play an important role in brain protection, as in response to ischemia or 
amyloid-induced cell death  105.  
 
Estrogen is one of the most studied steroid hormones 105 and is considered to be a 
psychoprotective hormone for diseases such as Alzheimer disease (AD) 106, and 
Parkinson disease, as well as depression since it interacts with dopaminergic neurons 
and involves dopaminergic brain structures in the basal ganglia that affect motor 
activity 84. Estrogen has also been linked to mood disorders, as the risk of developing 
depression is two times grater for women compared to men 107.  
 
Dihydrotestosterone 
Progesterone 
Cholesterol 
Pregnenolone 
Androstenedione 
Dehydroepiandrosterone (DHEA) 
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Estrogen and memory functions 
Some studies have found that performance in certain cognitive domains fluctuates 
during the normal menstrual cycle due to variability in hormonal levels 108. In both 
men and women estrogens are involved in memory processing 109-111. The estrogenic 
impact on memory seems to involve activity of cholinergic neurons in the hippocampus 
and basal forebrain 83,112. Thilers and coworkers conducted a longitudinal investigation 
of cognitive changes associated with menopausal transition in 193 women. They 
found that women within the normal range of BMI displayed more rapid decline of 
episodic memory than women with BMI > 25 113.  
 
Data is inconclusive concerning the role of hormone therapy (HT) on memory function. 
A systematic review of randomized controlled trials showed no consistent short-term 
benefit when HT was given during perimenopause or early postmenopause. When HT 
was initiated in the late postmenopause they found no evidence of benefit on episodic 
memory or other cognitive skills 114. A meta analytic review of randomized controlled 
trials and cohort studies showed that only women with menopausal symptoms improve 
their verbal memory, vigilance, reasoning, and motor speed with HT treatment. No 
benefits were observed in asymptomatic women 97. 
 
Estrogen has also been suggested to have a neuroprotective effect on AD 106  but 
studies on humans have shown inconclusive results. Some randomized, double-blind, 
placebo-controlled clinical trials have found that late onset of HT after natural 
menopause seems to increase the risk of dementia in women over 65 years of age 96,99. 
However population-based studies have shown a possible “window of opportunity” 
when HT was administered close to a natural or surgical menopause 108. In a recent 
population-based study where 1,768 women were followed, women who used any type 
of HT within 5 years of menopause had 30% less risk of AD especially if use was used 
for > 10 years. By contrast, the risk of AD was not reduced for those who had initiated 
HT > 5 years after menopause. The authors conclude that association of HT use and 
risk of AD may depend on timing. It might be beneficial if taken during a critical 
window near menopause, while initiated in later life may be associated with increased 
risk 115.  
 
1.2.1.2 Testosterone 
Androgens, such as testosterone, are vital sex hormones for both men and women. 
They act via androgen receptors located in different tissues in the body, including the 
CNS. In women, half of the testosterone arises from production in the ovaries and the 
remainder from the adrenals 116. In women the testosterone level is low with serum 
levels ranging from 0.7 – 3 nmol/l 117, while total testosterone in men ranges from  
10 – 30 nmol/l 118. Of the total circulating testosterone only 1-2% is free. 
Approximately 25% is weakly bound to albumin and the remainder is strongly bound 
to sex hormone-binding globuline (SHBG). Only the free and albumin fractions are 
biologically active119. 
 
Testosterone in both men and women can be aromatized to estrogen 84. Thus, a 
change in testosterone level during treatment also affects the level of serum estrogen. 
Furthermore, the balance and ratio between estradiol and testosterone may modulate 
cognitive functioning in women 120.  
 
Symptoms of androgen deficiency in women include a diminished sense of 
psychological well-being, fatigue, sexual function, and negative metabolic 
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consequences such as reduced bone density and muscle mass 14,121-124. Several 
testosterone treatment studies in women have found positive effects on psychosexual 
function and on both physiological and psychological well-being in women 125-130.  
 
While the effects of estrogen on memory functions in women are rather well known 
much less is known about the testosterone effect on the female brain 131. In men with 
androgen deficiency, testosterone treatment has been beneficial to verbal memory 
109,131; and in a small study on healthy volunteers, improvement in working memory 
was evident with testosterone treatment in older men but not in women 132. Few studies 
have investigated testosterone effect on cognition in women, and results have not been 
conclusive 133. A single supraphysiologic dose of testosterone in healthy women has 
resulted in increased visuospatial memory 134 and memory for location 135,136. In a study 
on women with polycystic ovary syndrome, which is associated with elevated 
testosterone levels, women performed worse on tests tapping abilities with which are 
associated  female advantage, such as verbal fluency 137. Verbal fluency improved 
while other cognitive and memory functions remained unchanged when free 
testosterone was reduced pharmacologically 138. A study on healthy naturally post-
menopausal women reported no support for beneficial effects on verbal fluency, 
verbal memory, or spatial ability with testosterone or estrogen treatment 139.  
 
 
1.2.2 Thyroid hormones 
Thyroid hormones (TH) are released by the thyroid gland and play a critical role in 
cellular metabolism in the brain and other organ systems 140. In the fetus TH are 
involved in the growth and development of the CNS and in adults thyroid dysfunction 
is associated with somatic, neurological and psychiatric abnormality 141,142. Deficiency 
of TH affects the migration, proliferation, survival, and differentiation of distinct 
neuronal cell populations in the fetus 140. 
 
Production of triiodothyronine (T3) and its prohormone thyroxine (T4) are activated by 
thyroid-stimulating hormone (TSH), of which the latter is synthesized from the anterior 
pituitary gland in response to TSH-releasing hormone. In serum, more than 99% of 
thyroid hormones are bound to specific proteins, such as T4 binding globulin and 
albumin 142. Only the free hormones are active in cells 143.  
 
TH are members of the nuclear receptor superfamily 144 . These mainly act on genomic 
level 141. A close relationship exists between THs and cholinergic system functions, 
especially in the basal forebrain and hippocampus 141.  
 
Few neuropsychological studies have examined the relationship of cognition to 
alternation in thyroid functions 143,145. However, T4 levels are associated with cognitive 
functioning. In a double-blind, randomized, cross-over study reported by Samuels and 
coworkers 146, hypothyroid patients were treated with two doses of T4, the larger of 
which corresponded to subclinical thyrotoxicosis while the smaller dose corresponded 
to euthyroidism. The larger dose was related to an increase in free T3 level and 
improvement in mood and motor learning, but not to other cognitive functions, such 
as working memory, or verbal or nonverbal declarative memory 146. 
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1.3 CLINICAL ASPECTS OF FATIGUE 
1.3.1 Mild Traumatic Brain Injury 
The incidence of mTBI in the industrialized world is estimated at 100 to 300 
cases per 100,000 in the population 147. How to define mTBI is though 
debated148. The American Congress of Rehabilitation Medicine established 
diagnostic criteria for mTBI: A traumatically induced physiological disruption 
of brain function, as manifested by at least one of the following: Any period of 
loss of consciousness (LOC) for up to 30 minutes; any loss of memory for 
events immediately before or after the accident but less than 24 hours; any 
alternation of mental state at the time of accident (e.g., feeling dazed, 
disoriented, or confused), but including that after 30 min the patient should 
score between 13–15 at Glasgow Coma Scale (GCS); and, focal neurological 
deficit that may or may not be transient 149.  
 
In mTBI the prognosis may be considered good even though symptoms of headache, 
fatigue, poor concentration, and memory difficulty persist well beyond the first days to 
weeks after a concussion, and for most patients full recovery is reached before 3-6 
months after the trauma 150. However, some patients report residual intellectual, 
emotional and behavioral symptoms 151,152 in addition to significant fatigue 4,5,7,20. The 
incidence of persistent cognitive disability after mTBI is debated. Meta-analytical 
studies have identified only minor disabilities occurring directly after the trauma and up 
to three months later 153.  
 
Among mTBI patients the amount of reported symptoms have been associated 
with insurance claims 147,150, low educational level, emotional distress, self 
reported fatigue 154,155 ,depression 156 and psychiatric disorders 157. The report of 
symptoms may not correspond to cognitive deficits since data are apparently 
subjected to patterns of both under and over reporting 158,159. Fatigue is, 
however, a major risk factor for a poorer prognosis when it comes to sick leave 
from work and poor quality of life 20. Investigating fatigue further might 
optimize rehabilitation in patients with persisting symptoms after mTBI. 
 
 
1.3.2 Oophorectomy 
Oophorectomy is the surgical removal of an ovary or ovaries. A consequence of 
bilateral oophorectomy is the abrupt decline of estrogen levels, as compared to a 
gradual decline after natural menopause. Post-surgical-menopause serum estrogen is 
decreased by about 90 % 160 and testosterone by half 161,162. The production of ovarian 
testosterone remains largely unchanged after natural menopause 161,163. This abrupt 
decline of sex steroid hormones often gives rise to menopausal symptoms 164. 
Guidelines recommend postmenopausal women younger than 45 years of age to take 
estrogen supplements until their natural age of menopause in order to preserve bone 
density 165. Testosterone supplementation, on the other hand, is seldom given. Little is 
known about the effects of androgen insufficiency on women’s health 14,117 
 
Different hormone profiles in oophorectomy versus natural menopause suggest that 
different treatments may be warranted to address symptomatology 165. The risk of 
cognitive impairment is higher among oophorectomized women who who did not 
receive estrogen until their predicted age of natural menopause 166.  
 
Even though testosterone levels do not decline as much as estrogen levels after 
oophorectomy, androgen insufficiency is a risk in these women. Complaints of 
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subjective fatigue have been reported, as well as a sense of diminished well-being, 
dysphoric mood, reduced sexual pleasure and negative vitality 14,121-124. In one study of 
the effects of testosterone on memory and cognition in younger recently  
oophorectomized women, Sherwin 167 compared treatment with estrogen-alone, 
estrogen-plus-androgen and androgen-alone. She found that estrogen-alone and 
estrogen-plus-testosterone had the same effect on memory functions. 
 
 
1.3.3 Graves’ disease 
Graves’ disease (GD) is one of the major autoimmune diseases with an estimated 
incidence in Sweden of 21/100,000 individuals 168. In GD, antibodies to the thyroid 
stimulating hormone receptor (TRAb) stimulate the thyroid stimulating hormone 
(TSH)-receptor, thereby increasing thyroid hormone synthesis and secretion. TRAb is a 
marker for the disease, which is also characterized by low levels of TSH, elevated 
thyroid hormones, free T4 and/or free T3 169. Female to male ratio in GD is 3.9:1 and 
the peak incidence occurs during the age span of 40-59 years of age 168. Both a genetic 
predisposition and environmental factors, such as moving from iodine deficiency areas 
to iodine sufficiency, have been proposed to increase the risk for the disease, but what 
actually triggers the onset is still unknown 169. Also, life style factors contribute to the 
onset of disease. Smoking has been associated with higher risk of GD and obesity with 
a relative lower risk of incidence 170.  
 
Physical and psychiatric symptoms may present early in GD, including weight loss, 
tachycardia, tremor, ophthalmopathy, poor vitality, sleep disorders, sensitivity to stress, 
anxiety, depression and irritability 171. Several studies have suggested a high prevalence 
of psychiatric symptoms in GD 172-174.  
 
Patients with GD are often initially treated with methimazole, which blocks thyroxine 
synthesis, and after two weeks thyroxin may be added or methimazole may be used as a 
single therapy. With 18 months of this treatment the chance of complete remission is 
about 50 %. Despite that somewhat positive outlook, the patient is in a euthyroid state 
during the ensuing 16-17 months and some patients do not feel recovered. Some studies 
report diminished vitality and quality of life and residual cognitive problems many 
years after treatment 15,16,175-177. Depression and complaints of lacking energy are 
common and in some cases patients despite having full-time jobs are not able to return 
previous their work level as before onset 16. According to a Swedish long term follow 
up study, the feeling of not being fully recovered can persist several years, though it 
does not seem to be related to levels of thyroid hormones or TSH 177. 
 
Neuropsychological investigation is conspicuously lacking in the literature on GD. A 
few studies on newly diagnosed (untreated) GD patients show mild deficits in attention 
178, memory, and complex problem solving 179, while others have found no cognitive 
effects 173. There is a lack of correspondence between thyroid hormone levels and 
symptoms 180 and with neuropsychological findings 173,178. Clinically, high free T3 and 
free T4 levels have been associated to severity of disease 169. No study has focused on 
fatigue in patients with untreated GD although complaints of fatigue, tiredness and 
unstable energy are common in treated GD patients 15,16.  
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2 AIMS OF THE THESIS 
 
This thesis aims to examine the possibilities to capture cognitive fatigue with 
established neuropsychological methodology. Furthermore to explore whether specific 
hormones and hormone replacement therapy may influence cognitive fatigue and 
neuropsychological performance.  
 
 
Aims of each study were as follows: 
 
• To investigate if cognitive fatigue is possible to capture using 
neuropsychological tests on patients with persisting symptoms after a mTBI. 
Further to investigate if cognitive fatigue is independent from depression and 
sleep disorders in this patient group.  
 
• To study if additional testosterone treatment, in combination with estrogen 
replacement, improves subjective and objective measures of memory compared 
to estrogen treatment alone in oophorectomized women.  
 
• To explore if cognitive fatigue is present in oophorectomized women and if this 
treatment regimen is related to self perceived physical and psychological well-
being, as well as estrogen and testosterone serum levels.  
 
• To investigate if subjective as well as cognitive fatigue are present among 
patients with untreated Graves’ disease. Further to study if this is related to 
depression, sleep disturbances, hormonal changes or other neuropsychological 
dysfunctions.  
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3 METHODS 
3.1 PARTICIPANTS  
3.1.1 Patients in Study I 
The sample consisted of 24 consecutively enrolled patients (12 women and 12 men), 
aged between 18 and 51 years (mean 35.7 ± 9.8 years) each referred for a 
neuropsychological investigation due to persistent cognitive complaints associated with 
their mTBI. Nine patients were recruited from the Department of Rehabilitation 
Medicine, Danderyd Hospital, Stockholm: 9 patients from Kullbergska Hospital, 
Katrineholm; 5 from Nyköping Hospital; and 1 patient from Mälarsjukhuset Hospital, 
Eskilstuna. Age was stratified (18-50 years) to reduce variance due to the risk of 
cognitive decline due to preclinical dementia and stroke in the older participants and the 
risk of developmental differences in the younger participants. As one of the patients 
was 50 years during enrolment but became 51 before assessment, the range was 
adjusted to 18-51 years of age. The mean length of formal education was 12.0 ± 1.5 
(range 9 – 16 years) and mean time from trauma to the neuropsychological assessment 
was 21 ± 19 months with a range of 4 – 70 months. 
 
All patients had post-concussional symptoms of at least 3 months but less than 6 years 
in duration since the time of trauma. All fulfilled the criteria of mTBI according to the 
American Congress of Rehabilitation Medicine; traumatically induced physiological 
disruption of brain function, as manifested by at least one of the following: 
• a period of loss of consciousness (LOC) of up to 30 minutes;  
• any loss of memory for events immediately before or after the accident but with 
a duration of less than 24 hours;  
• any alternation of mental state at the time of accident; score on the Glasgow 
Coma Scale (GCS) administered after 30 min from trauma between 13 and15;  
• presence of focal neurological deficit that may or may not have been transient. 
 
Clinical characteristics of the patients are presented in Table 2. 
 
Table 2. Injury related information for the mTBI patients (n = 24).  
Characteristics       count     Characteristics    count  
Type of accident        n (%)           Anterograd amnesia       n (%) 
 Fall          8 (33)          None           4 (17)   
 Car accident        9 (38)          1-5 min               2 (8)  
 Assault          2 (8)             6-45 min         7 (29)  
 Bi- or motorcycle accident    2 (8)            > 45 min         4 (17) 
 Other          3 (12)         uncertain but <60 min   7 (29)   
 
Retrograde amnesia                  Loss of consciousness    
None             16 (67)          None          7 (29) 
 < 1 min        2 (8)           < 1 min           1 (4) 
 1-5 min        3 (12)           1-5 min          6 (25)   
  > 5 min         2 (8)           6-30 min         5 (21) 
 Missing        1 (4)            uncertain but <30 min    5 (21)  
 
Patients were excluded from participation if one was uncertain of the time of LOC (as 
may occur with comorbid alcohol intoxication), had taken medication that could 
interfere with neuropsychological test results, suffered from dementia evidenced from 
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CT-scans, diagnosed with hydrocephalus or subdural heamatoma after the trauma, or 
was known to have had seizures or severe psychiatric disease prior to the head injury. 
Also, patients who did not fully comprehend or speak Swedish were excluded as 
several tests demanded verbal comprehension. Information about current medication 
was obtained from interview data and hospital records. At the inclusion none of the 
participants abused alcohol or illicit drugs.  
 
Six patients showed imaging abnormalities. One patient had a small bleed in the 
cisterna magna, one had a small contusion hemorrhage in the right side of the basal 
ganglia, one had bilateral hemorrhages in the temporal lobe, and one showed a skull 
fracture but with no injuries in the brain parenchyma. Two additional patients had 
abnormalities that were less likely to be injury related: One had diffuse, periventricular 
white-matter lesions and a one had diffuse white-matter lesions at the back horn of the 
left lateral ventricle. In the last case, abnormalities were not present during ordinary 
MR sequences but were visible on diffuse tensor imaging (DTI) sequence.  
 
 
3.1.2 Patients in Study II and III 
From the patient discharge register of Stockholm county, women aged from 45 to 60 
years of age, who had undergone hysterectomy plus bilateral salphingo-oophorectomy 
for benign disease, were invited to participate in the study.  
 
Inclusion criteria were: Age between 45-60 years; BMI between 18-29 kg/m²; blood 
pressure below 170/105 mm Hg; normal liver enzymes; and a normal mammogram 
within the last 12 months. Sexual dysfunction or decreased psychological well-being 
was not mandatory for inclusion. 
 
The exclusion criteria comprised of the use of  HT within the last two months; 
concomitant medication (e.g. lipid lowering agents, other sex hormones, calcium-
antagonists, beta-blockers, tranquillizers barbiturates, and antihistamines); history of 
premalignancy/malignancy, liver disease, lipid disorder, a cardiovascular, 
cerebrovascular or trombo-embolic event; and current psychiatric disease, alcohol 
abuse or smoking >10 cigarettes/day 181,182. 
 
A total of 65 women were assessed for eligibility during a recruitment period of 6 
months. Of these women, 15 did not fulfill the inclusion criteria. Fifty consecutive 
women were recruited. At time of inclusion the mean age was 54.0 ± 2.9 years (range 
46-60 years), mean body mass index 25.7 ± 2.8 kg/m² and mean time since 
oophorectomy 4.6 ± 2.4 years. Six women (three from each group) discontinued the 
study, five due to poor drug compliance and one due to migraine during the estrogen 
treatment. Forty-four women were included in the analyses. 
 
 
3.1.3 Patients in Study IV 
The sample consisted of 44 consecutive patients (35 women and 9 men), each newly 
diagnosed with a first time incidence of GD, and who were recruited from the three 
endocrinology departments in the county council of Sörmland. Patients with severe 
dyslexia (n=4) and/or history of mild traumatic brain injury (n=6) were excluded from 
further analyses in this study. Subsequent analyses were carried out on the 34 
remaining patients (28 women and 6 men). Failure analyses showed that the excluded 
patients scored higher on fatigue severity scale (p = .045) but revealed no significant 
differences on neuropsychological tests. The mean age among the remaining patients 
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(n=34) was 39.2 ± 9.8 years (range: 18 – 51 years) and mean length of formal 
education was 12.2 ± 2.2 years (range 9 – 17 years). All participants had elevated 
peripheral thyroid hormones and suppressed TSH. All but one of the 34 patients had 
elevated TRAb. This patient had an increased even diffuse distribution on a 
radionuclide scan.  
 
Exclusion criteria were: medication that could interfere with neuropsychological test 
results, patients suffering from dementia, seizures or severe psychiatric disease. Also 
patients who did not fully comprehend or speak Swedish were excluded as several tests 
demanded verbal comprehension. Information about current medication was obtained 
from an interview and hospital records. Beyond the 44 included patients eight patients 
declined to participate, one patient had indication for operation and one patient was 
missed due to administrational misses, although the patients otherwise met the 
inclusion criteria.  
 
Treatment with anti-thyroid medication was not allowed prior to neuropsychological 
assessment. However, in cases of tachycardia and/or tremor beta-blockers were allowed 
(16 patients used beta-blockers at the neuropsychological assessment). One patient had 
hypertension and used an angiotensin-converting-enzyme inhibitor; three were on anti-
depressant pharmacotherapy.  
 
Eleven patients were smokers while 23 were non-smokers. Two patients were smokers 
until 1 week before the neuropsychological assessment and were scored as smokers. At 
inclusion none of the participants abused alcohol or illicit drugs. 
 
 
3.1.4 Controls in Study I and IV 
A control group (n=34) was recruited via advertisement and friends to hospital staff. 
Age was stratified between 18-50 years. Three of the controls were excluded; two due 
to a mild head injury and one due to encephalitis not reported prior to the assessment. 
Thirty one controls remained for further analyses. The mean age for the remaining 
controls (n = 31, 18 women and 13 men) was 36.7 ± 8.8 years (range 20 - 49 years) and 
the mean length of formal education was 13.1 ± 1.9 years (range 11 – 17.5 years). 
Twenty-nine of the 31 controls were right handed. 
 
Three controls with asthma used inhalation therapy and one used antidepressant 
pharmacotherapy, all the other controls were free of medication. Four of the controls 
smoked and 22 were non smokers. One control smoked less than 20 cigarettes yearly 
and was scored as non-smoker. Information regarding smoking was missing for five of 
the controls. At inclusion none of the controls were addicted to alcohol or illicit drugs. 
 
The controls were offered a gift certificate (500 Swedish kronor) and an optional 
feedback session of individual test performance profile after full participation. All 
controls were required to be fluent in Swedish. 
 
 
3.2 PROCEDURES AND MEASURES 
3.2.1 Assessment 
3.2.1.1  Study I and IV 
The neuropsychological tests were administered in an outpatient setting. The patients 
and controls were assessed on at least two occasions by individual neuropsychologists 
competent to administer the test battery in a consistent manner. For the patients in 
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Study IV the neuropsychological assessment took place before a maximum span of 7 
days lapsed from diagnosis to assessment. 
 
3.2.1.2 Study II and III 
A randomized, double-blind, crossover and placebo controlled study. Fortyfour  
oophorectomized women were treated with either estrogen + placebo or estrogen + 
testosterone for 24 weeks; and then the treatments were switched. Only testosterone 
and placebo were randomized. Estrogen was administered to every woman.The 
medication used in the study was individually numbered for each subject. No one 
monitoring the study had access to the randomization list. Both testosterone 
undecanoate and placebo tablets were manufactured by the same pharmaceutical 
company and had identical appearances and packages. 
 
Blinding was maintained until completion of the study. After inclusion and a washout 
period of two months the women were randomly assigned to receive oral treatment 
with either estradiol valerate 2 mg + testosterone undecanoate 40 mg (E/T) daily or 
estradiol valerate 2 mg + placebo (E/P) daily. The women were monitored and assessed 
with neuropsychological tests by trained research nurses before treatment, after 24 
weeks (at crossover) and after 48 weeks (at end of study). The assessment was 
supervised by a neuropsychologist. 
 
 
3.2.2 Measurements and definitions 
In Studies I and IV patients and controls were assessed using a comprehensive battery 
of neuropsychological tests (Table 3). Tests relevant to this thesis are described here.  
 
Table 3. Tests, subtests and questionnaires used in the comprehensive mTBI study.   
Tests         Questionnaires      
- WAIS-III Information (1a/1a)*      - Rivermead Post Concussion  
- WAIS-III Digit Span (2a/2a)*           Questionnaire (expanded version)  
- WAIS-III NI Block Span (3a/3a)*     - Hospital Anxiety and Depression  
- WAIS-III NI Digit Symbol (4a/4a)*            Scale (HADS) 
- WAIS III: Letter-Number Sequencing (5a/5a)*  - Impact of Event Scale (H) 
- WAIS III: Matrix Reasoning (6a/6a)*     - Fatigue severity scale (FSS) (H) 
- Buschke Selective Reminding Test (1b/1b)*   - Everyday Consequences of Fatigue  
- Rey-Osterrieth Complex Figure Test            (ECF) (H) 
  (BQSS) (2b/2b)*          - Pittsburgh Sleep Index 
- FAS (Controlled Word Association Test (3b/3b)*    Questionnaire (PSIQ)(H) 
- Design Fluency Test (fixed, 4 min.) (4b/4b)*   - Örebro Musculoskeletal Pain     
- Trail Making Test (TMT) (5b/5b)*        Screening Questionnaire (H) 
- Ruff 2 & 7 Selective Attention Test (6b/6b)*   - Swedish Universities Scales of   
- Motor functions from Luria battery (1c/7a)*      Personality (SSP) (H)  
- Grooved Pegboard Test (2c/8a)*      - State-Trait Anxiety Inventory      
- Color-Word Test (Stroop test) (3c/8b)*           (STAI) (H) 
- Iowa Gambling Test (4c/7b)*#             
- Rey 15 Item (5c/10a)*              
- Levels of Emotional Awareness Scale (LEAS)(6c/9a)*#   
- Sniffn’ Sticks (screening 12 version) (7c/9b)*              
*  = test order numbered and occasion in letters for patients/controls respectively 
# = not in study IV 
H= completed at home before assessment 
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3.2.2.1 Neuropsychological tests reported in this thesis 
Buschke Selective Reminding Test (BSRT) measures verbal learning and memory 183. 
Scores for number of immediately recalled words and recalled after a 30-minute delay 
are obtained. Low scores for the former indicate poor immediate retention, while the 
latter indicate poor verbal learning. To accommodate the treatment feature of Study IV 
the parallel version of SRT test was used for half of the patients. There was no 
significant difference in difficulty level between the parallel versions (Study IV). 
 
Color-Word Test (CWT) / Stroop Test taps executive functions and measures 
inhibition184. A Swedish version of the CWT test was used 185. The pretest consists of 
ten rows of ten blue, red, green or yellow colored “XXX” letters and the main test 
consists of ten color words in contradictory colors per row, e.g. the word “red” is 
written in green letters and the subject has to say “green” and not “red. The discrepancy 
between the total time required to perform the pretest and the total time required to 
perform the main test is presented as the “Stroop effect” (Studies I and IV).  
 
Dynamic Motor Functions (from Luria battery) screens for several types of motor 
functions such as simple coordination, kinesthetic and dynamic motor functions and 
inhibition. This test is a short version of tasks included in the Luria battery  186,187 
(Appendix 10.1). A high score indicates good dynamic motor functioning (Study IV). 
 
FAS/COWAT evaluates phonemic fluency evidenced by the spontaneous production of 
words under restricted conditions. One minute each for words beginning with F, A and 
S, respectively. Participants are instructed not to use proper nouns and numbers, which 
are not tallied in the total number of accurate words produced 79,188. As Study IV is part 
of a larger treatment study a parallel version was used for half of the patients. In this 
version the letters K, O, and R were used. There was no significant difference in 
difficulty level between the two versions (Study IV). 
 
Grooved  Pegboard Test measures motor precision and motor speed 184. The 
participants are asked to place 25 grooved metal pegs into matching holes on a board as 
fast as they can. In this study a mean score each for the right and left hand is presented. 
Low scores indicate faster performance (Study IV). 
 
Rey 15-item 79 is used as a test of effort on memory testing during assessment. Patients 
and controls with a score less than 9 were excluded (Studies I and IV).  
 
Rivermead Behavioural Memory Test (RBMT) a practical measure of memory. Verbal 
learning was measured by reproduction of a logical story - immediate recall, and 
episodic memory - delayed recall after about 15 - 20 min. Three parallel versions of the 
stories were used 189. There was no significant difference in difficulty level between the 
parallel versions (Study II)  
 
Ruff 2 & 7 Selective Attention Test (Ruff 2 & 7 SAT) measures visual automatic 
detection speed and accuracy and controlled search speed and accuracy 80. The subject 
has to cancel the numbers 2 and 7 in a row of letters (Automatic Detection Speed) or 
among other numbers (Controlled Search Speed) 15 sec/section under a period of 5 
minutes. The number of correct cancellations (speed) was counted (Studies I and IV). 
 
Trail Making Test – Trails A and B. Trails A measures attention, perceptual 
organization and speed. The test requires the subject to connect 25 numbered randomly 
arranged circles by pencil lines in proper order. Trails - B measures attention, 
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perceptual organization, speed, and mental flexibility. The test requires the subject to 
connect 25 encircled numbers and letters, by a pencil, in alternating order The time to 
perform the test is measured 79,188. Low score means fast performance (Study IV). 
 
WAIS-III and WAIS-R Digit Span - repetition of digits-forward is considered to assess 
verbal attention span and backward repetition of digits (digits-backward) is considered 
to assess working memory 79,190,191. In this study the standard procedure from the 
WAIS-III and WAIS-R manual was used, i.e. the length of number series is 
successively increased until the subject fails two attempts at accurate repetition of a 
series of numbers. The scores are obtained for total sum forward and backward, 
respectively. In Study IV a discrepancy score between maximum forward and 
backward span length was calculated since the working memory component is related 
to the ability to recall the digits forward 79, the more negative score the poorer working 
memory (Studies II and IV). 
 
WAIS-III Digit Symbol is a multi-factorial subtest, originally used for measuring 
psychomotor processing speed 191. The test consists of rows containing small blank 
frames, each paired with randomly assigned number from one to nine. Above these 
frames is a printed key that pairs each number with a symbol. This 120-second, timed 
task requires one to fill in blank spaces with a symbol that is paired to the number. The 
score is the numbers of squares correctly filled in. Digit Symbol demands visual 
detection ability and learning capacity 79. Since psychomotor speed is also influenced 
by incidental learning capacity, memory function was investigated by measuring 
incidental memory after four completed rows by requesting the test subjects to fill out 
the correct symbol under each digit twice/digit 78 (Studies I and IV).  
 
WAIS-III Information is a subtest measuring premorbid educational and intellectual 
level, and is also a test of declarative memory 79,188,191 (Study I). 
 
WAIS-III NI Block Span as a nonverbal subtest corresponds to the Digit Span. The 
participants are instructed to tap fixed blocks in a given order indicated by the test 
leader. Two trials for each span are allowed. The test is terminated when the patient 
makes two errors at the same length of span 78,192. In this study the standard procedure 
from the WAIS-R and WAIS-III manual was used, i.e. the length of block series is 
successively increased until the subject fails two attempts at accurate repetition of a 
series of blocks. The scores obtained are the total sums, forward and backward, 
respectively. In Study IV a discrepancy score between maximum forward and 
backward span length was calculated as the working memory component is related to 
the ability to recall the forward order of the blocks 79. The more negative score the 
poorer working memory (Study IV (Study IV). 
 
WAIS-R Digit Symbol Test is an older version to the WAIS-III Digit Symbol. The 
procedure is as in WAIS-III but the requested time is 90 seconds instead of 120 seconds 
190. Two parallel versions of the test were used. There were no significant differences 
between the two versions. Incidental memory was measured after three completed 
rows. Paired recall was measured in a string of 25 digits in random order, by memory 
after three completed lines and at free recall, the participants were asked to write down 
the symbols without connecting them to a given digit 79. Spatial errors were considered 
to occur when subjects rotate a symbol but otherwise correctly place it; these errors 
were recorded as well. The percent of possible rotations had to be calculated, due to the 
fact that the symbols O and X cannot be rotated (Studies II and III).  
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The cognitive fatigue measures were operationalized as follows:  
A measure of psychomotor fatigue (DST-f) was derived from WAIS-NI procedure 78 of 
performance on the Digit Symbol Test by subtracting the number of digits produced in 
the first 30 seconds from the number of digits produced in the last 30 seconds, while 
still within the time interval of 120 seconds for WAIS III and 90 seconds for WAIS-R 
78,190-192. A DST-f (difference) less than or equal to “0”, indicated cognitive fatigue 78. 
Since the fatigue measure also could be affected by decreased incidental learning 
capacity, this was controlled for by measuring incidental memory 78,192.  
 
Executive fatigue (CWT-f) is derived from a Swedish version of the Color Word Test 
185. Speed was recorded for every second row. Total time (in seconds) to name the color 
words in the first two rows is subtracted from total time to name color words in two last 
rows of the test. A positive score indicates slower performance during the end of the 
test and, thereby, fatigue. 
 
Attention fatigue was measured by the Ruff 2 & 7 SAT as follows: Results from the 
first two sections of detection speed (number of correct cancelled 2 and 7) subtracted 
from the two last sections would measure automatic detection fatigue (ADS-f). 
Subtracting the first two rows of controlled search speed from the two last rows gave a 
measure of controlled search fatigue (CSS-f). A negative score would indicate a slower 
performance speed at the end of the test defined as fatigue.  
 
3.2.2.2 Questionnaires reported in this thesis 
Everyday Consequences of Fatigue (ECF) is a questionnaire designed for these studies, 
covering five everyday consequences of fatigue (Appendix 10.2). The participants rate 
how often fatigue made them fall asleep during daytime or early evening while they 
were inactive, caused them to take naps or yawn excessively, and prohibited them from 
doing mentally or physically demanding tasks. The scale ranges from “not during the 
last month” (0 points) to “at least three times a week” (5 points). The maximum score 
of 25 indicates a high fatigue impact on everyday activities (Studies I and IV).  
 
Fatigue Severity Scale (FSS) measures subjective symptoms of fatigue 27,193 and 
comprises nine questions covering the behavioral consequences of fatigue. It has been 
proven to be a sensitive measure of fatigue among TBI patients 46. Each item is scored 
on a 7-point Likert scale. A high mean score is equivalent to a high level of fatigue 
(Studies I and IV). 
 
Hospital Anxiety and Depression Scale (HADS) is used to indicate depression and 
anxiety. A score > 10 points  on the HADS depression subscale indicates that the 
participant suffers from depression 194 (Studies I and IV).  
 
Pittsburgh Sleep Quality Index (PSQI) is a questionnaire used to assess different sleep 
disorders such as subjective sleep quality, insomnia, sleep distractors etc. There are 
seven items with ratings from 1-3, with a maximum summed score of 21. A high score 
indicates poor sleep quality 195 (Studies I and IV). 
 
Self reported memory was assessed with a questionnaire of subjective memory 
problems (QSMP), which is a self-administered questionnaire covering everyday 
memory problems (Appendix 10.3). A maximum score of 36 indicates severe memory 
problems. The questions were derived from the more comprehensive Cognitive Failure 
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Questionnaire - used in clinical practice at Danderyd Hospital and not validated in other 
research studies (Study II). 
 
The Psychological General Well-Being Index (PGWB) was used to assess affective or 
emotional states reflecting subjective well-being or distress. The questionnaire consists 
of 22 items forming six subscales (anxiety, mood, well-being, self-control, general 
health, and vitality) and a total index score 196 (Study III).  
 
3.2.2.3 Hormone assays 
3.2.2.3.1 Study II and III 
The serum concentrations of total testosterone (T) were determined with 
radioimmunoassay (RIA) in untreated serum. The serum concentrations of SHBG and 
estradiol (E2) were determined by chemiluminescence. The apparent concentrations of 
free T were calculated from values for total T, SHBG and a fixed albumin 
concentration of 40 g/l by successive approximation, using a computer program based 
on an equation system derived from the law of mass action 197.  
 
3.2.2.3.2 Study IV 
Venous blood samples were collected at baseline before the neuropsychological 
assessment took place. Serum concentrations of free T3, free T4, TRAb, TSH, 
tyreoperoxidas autoantibodies (TPO), were collected as were hemoglobin, calcium, 
albumin, and creatinin. Concentrations of TSH, free T3 and free T4 and anti-TPO 
antibodies were measured by chemiluminescent methods. Thyrotropin receptor 
antibodies were measured by radioimmunoassay. Remaining samples were analyzed by 
routine laboratory work. 
 
No hormonal samples were collected from the controls. 
 
 
3.2.3 Power calculations and statistical analyses  
3.2.3.1 Study I  
A power calculation on the DST fatigue measure was performed. For a mean score 
difference between patients and controls of 2.5, a SD of 3.0, an alpha level of 0.05, and 
a power of 0.80 a sample of 24 patients and 24 controls was sufficient.  
 
Mann-Whitney U-test was used for comparison between patients and controls. 
Spearman’s rank correlation were used even when the variables were normally 
distributed. In order to avoid the risk of obtaining false positives due to the number of 
variables entered in analysis, Bonferroni correction was applied. Binary logistic 
regression analyses were used to analyze factors potentially contributing to 
psychomotor fatigue. Medications were classified in two groups:  
1. No medications 
2. Medications (e.g., acetylsalicylic acid, paracetamol, ibuprofen, terbutaline, 
vitamins, pregabalin, codeine, tramadol, zopiclone, amitriptyline, citalopram, 
hydroxyzine). 
Both forward and backward, stepwise logistic regression were used to check for 
multicollinearity.  
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3.2.3.2 Studies II and III  
A power calculation on cognitive fatigue (WAIS-III digit symbol test) was based on 
an assumption of a treatment effect of 1.0 score, SD of 2.04, an alpha level of 0.05, 
and a power of 80. This would demand a sample size of 35 individuals.  
Parametric methods were used for normally distributed variables with interval-level 
data (Student’s t-test for paired samples and Pearson’s product-moment correlation), 
and non-parametric methods were used when the ordinal data was skewed (Wilcoxon 
matched-pairs ranks test and Spearman’s rank correlation test). In Study III, post hoc 
analyses of comparisons between subgroups. Student’s t-test for independent samples 
was used. For comparison between dichotomized variables (> the 75:e percentile and  
< the 75 percentile) Fisher’s exact test was used. The possible effects of randomization 
bias were investigated using a linear mixed-model analysis including one within-group 
factor treatment and one between-group factor.  
 
3.2.3.3 Study IV  
Power calculations were the same as in Study I above. 
 
Parametric methods were used for normally distributed variables with interval-level 
data, and non-parametric methods were used for skewed and for ordinal data. For 
categorical data χ2 and Fisher’s exact test were used. To correct for gender influences on 
the neuropsychological measures a one-way ANOVA, with gender as a covariate, was 
performed: and to correct for false positives due to the number of analyses, a 
Bonferroni correction was applied. For ad hoc analysis to examine contribution of 
factors to cognitive fatigue, binary logistic regression analysis was used. Both forward 
and backward stepwise logistic regression was used. Both methods revealed the same 
results indicating that there were no problems with multicollinearity. The results from 
backward logistic regression will be presented.  
 
In all studies two-tailed p-values were used with a critical significance level of 0.05. 
SPSS statistics 19 was used for the analyses. 
 
 
3.3 ETHICAL CONSIDERATIONS 
All participants gave informed consent to take part in the studies. The research was 
carried out in accordance with the Declaration of Helsinki (2000) and was approved 
by the Regional Ethical Board in Stockholm.   
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4 RESULTS 
4.1 STUDY I 
The mTBI patients performed significantly poorer on the complex neuropsychological 
fatigue measures (DST-f and CWT-f) compared to the healthy controls (Figure 3).  
 
Neither age, years of formal education, nor depression correlated with any of the 
cognitive fatigue measures. However self-rated sleep disturbances (PSQI) correlated 
with executive fatigue (CWT-f) (rs(21) .503, p = .020) among patients but not among 
controls.  
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Figure 3. Results on the different cognitive fatigue measures for mTBI patients  
(n =  24) and controls (n = 31). Abbreviations: DST-f (Digit Symbol-derived fatigue 
score), ADS-f (Ruff 2 & 7 - attention detection speed, derived fatigue score), CSS-f 
(Ruff 2 & 7 - controlled search speed, derived fatigue score), CWT-f (Color Word, 
derived fatigue score).  
 
 
Compared with controls, mTBI patients self-rated fatigue significantly higher  
(p = .001) on both FSS and ECF; but they also scored sleep quality and depression each 
poorer (Figure 4).  
 
Among the patients depression (HADS) correlated positively with self-rated fatigue 
(FSS) (r(23) .568, p = .005) and sleep symptom ratings (PSQI) (r(24) .584,  
p = .003) but not with everyday consequences of fatigue (ECF) r(24) .285,  p = .177). 
Five of the patients scored > 10 on the HADS depression subscale. 
 
The only correlation found between the self-rated fatigue measures and cognitive 
fatigue measures was between FSS and executive fatigue (CWT-f) among the patients 
(r(21) .539, p = .012). 
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Figure 4. Results on self-rated measures for mTBI patients (n = 24) and  
controls (n = 31). Abbreviations: FSS (Fatigue Severity Scale), ECF  
(Everyday Consequences of Fatigue), PSQI (Pittsburgh Sleep Quality  
Index), HADS (Hospital Anxiety and Depression Scale). 
 
 
The mTBI patients exhibited descending performance speed, between the first and last 
30 seconds on the DST-f measure while the controls accelerated their performance 
speed (Figure 5). Fifteen (62 %) of the 24 patients and 6 (19 %) of the 31 controls 
showed a non-ascending speed on the DST. Logistic regression analyses showed that 
neither educational level nor memory for symbols contributed to the results. 
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Figure 5. Numbers of symbols produced in the first 30 seconds compared to  
in the last 30 seconds on the WAIS-III Digit Symbol Test for mTBI patients 
(n = 24) and controls (n = 31) respectively.  
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As five patients scored high on the HADS depression subscale, the analyses were rerun 
without these patients (n = 19). The results on psychomotor fatigue were the same as 
before (p = .002); but with their omission executive fatigue was no longer significant  
(p = .051). The attention measures were not significant on ADS-f (p = .099) and CSS-f 
(p = .415). 
 
 
4.2 STUDY II 
The memory improved from baseline with both treatment regimens. Immediate recall 
performance, measured by the RBMT, significantly improved with estrogen+ placebo 
treatment as well as with estrogen+ testosterone (Figure 6).  
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Figure 6. Memory functions for baseline and the two treatment regimens.  
B = baseline, E/P = estrogen + placebo regimen, E/T = estrogen + testosterone regimen. 
 
 
At baseline estrogen levels did not correlate to any of the cognitive measures 
while total testosterone showed a negative correlation to immediate recall on 
RBMT (rs(44) = - .350, p = .020).  
 
During the estrogen + placebo regimen the estrogen level correlated positively 
with free recall of digits (rs(44) = .358, p = .035). Total testosterone did not 
correlate with any of the cognitive measures while free testosterone showed a 
negative correlation with immediate recall on the RBMT (rs(42) = - .349, p = 
.023) and working memory (WAIS- R Digit Span backwards) (rs(39) = - .316,  
p = .050).  
 
During the estrogen + testosterone regimen hormonal levels did not correlate 
with memory functioning. 
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4.3 STUDY III 
At baseline, when the hormone levels were very low, 20 of 43 women (46 %, one 
missing case) showed cognitive fatigue – defined as a non-ascending result on the 
test. Incidental memory did not explain the psychomotor fatigue as the DST-f 
measure did not correlate with recall of digits.  
 
Performance on the DST-f did not correlate with sex hormone levels at baseline. 
However, DST-f correlated with PGWB - general health (rs(43) = .35; p = .02) 
and with self-control (rs (43) = .32, p = .04); and correlated negatively to BMI  
(rs(43) = - .32, p = .04). This pattern in PGWB subscales were also present when 
the women were divided into fatigue (n = 20) or non-fatigue (n = 23) groups 
(Figure 7). 
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Figure 7. Results on the PGWB subscales at baseline for fatigue (n = 20) vs. non 
fatigue (n = 23) women at baseline 
 
 
We found no treatment effects after 24 weeks of treatment with estrogen plus 
testosterone, compared to estrogen plus placebo. No significant correlation 
resulted from comparison of hormonal level with DST-f.  
 
During the estrogen plus testosterone treatment, 8 of 9 women with the highest E/T 
ratio (> 75 percentile) tended to show cognitive fatigue (Fisher’s exact test, p = .06,). 
During the estrogen plus placebo treatment 20 of 29 women with an E/T ratio <75 
showed cognitive fatigue (Fisher’s exact test, p = .04).  
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4.4 STUDY IV 
Seventeen GD patients showed cognitive fatigue (non ascending speed on the DST-f) 
compared to six of the controls (p = 0.01).  
 
Significant findings were obtained on several self-report fatigue, sleep quality and 
depression measures. Patient status elicited significantly more severe fatigue, greater 
consequence in everyday life due to fatigue, poor sleep quality, and elevated depression 
(Table 4). 
 
 
Table 4. Results obtained from on questionnaires. Means ± standard deviations are  
presented.  
Questionnaires    patients (n=34)  controls (n=31) p-level  
FSS - mean score     4.4 ± 1.4            2.3 ± 0.8     p <.001 
ECF - total score     9.8 ± 5.8            4.4 ± 3.5   p <.001 
PSQI - total score     8.2 ± 3.4            4.7 ± 3.1     p <.001 
HADS - total score    13.2 ± 8.7            3.4 ± 2.7     p <.001 
   - anxiety score    8.2 ± 5.4            2.6 ± 2.4     p <.001 
   - depression score   5.0 ± 4.0              .8 ±   .8     p <.001  
Mann-Whitney U test is used for comparison. 
Abbreviations: HADS (Hospital Anxiety and Depression Scale), FSS (Fatigue  
Severity Scale), ECF (Every day Consequences of Fatigue), PSQI (Pittsburgh Sleep  
Quality Index). Bonferroni corrected significance level is p = .008  
 
 
Individual patient group HADS scores correlated with FSS (rs(34) = .507, p = .002), 
ECF (rs(34) = .498,  p = .003), and PSQI  (rs(34) = .427, p = .012).  
 
No significant differences in HADS scores were obtained between fatigue (n=17) and 
non-fatigue (n=17) GD patients (5.5 ± 4.4 vs. 4.5 ± 3.6) (Z = 0.64, p = .521); and 
neither were significant differences found with age, number of smokers, hormone 
levels or self-rated measures between the fatigue and non-fatigue patients. However, 
the fatigue patients had lower educational level than the non fatigue (11.5 ± 1.6 vs. 12.9 
± 2.5) (Z = -2.06, p = .039) and there fewer users of beta-blockers among the fatigue  
(n = 5) compared to the non fatigue patients (n = 11) (p = .039). Logistic regression 
analysis disclaimed lower length of educational level as an explanation for cognitive 
fatigue among GD patients.  
 
The GD patients performed significantly poorer on the test of dynamic motor functions 
(p = .006), perceptual organization (p = .008) incidental memory (p = .010), verbal 
learning (p = .012), verbal working memory (p = .006) and word generation (p = .002) 
compared to the controls, when gender differences were controlled for.  
 
Among the patients free T3 levels correlated positively with faster performance in 
motor precision (Grooved Pegboard Test) (p = .013) and visual organization (Test, 
Trail Making Test - A) (p = .007), better automatic attention speed (p = .037), 
controlled search speed (p = .043) (Ruff 2&7), incidental memory on DST (p = .009), 
and better inhibition (Stroop effect on CWT) (p = .004). Free T 3 also correlated to high 
scores of every day consequences of fatigue (ECF) rs (29) .445, p = .015, but not to 
cognitive fatigue. Also no correlations were found between hormone levels and 
depression, anxiety or sleep quality. 
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5 DISCUSSION 
5.1 COMMENTS ON MAIN FINDINGS 
5.1.1 Capturing fatigue with neuropsychological methods  
Study I showed, in line with the hypothesis, that tests demanding a coordination of 
complex cognitive functions including higher order attention 35 , “executive control” 198 
and working memory  199 as well as motor behavior 31,39,200 could be more suitable to 
measure cognitive fatigue compared to less cognitive challenging tests. 
 
The DST-f score is derived from the WAIS Digit Symbol Test, which is a complex test 
and sensitive to many different kind of neuropsychological dysfunctions 79. Compared 
to performance on a simple graphomotor test, performance on the DST involves 
bilateral activation in predominantly right side, inferior frontal regions 201. 
Theoretically, more “functionally clean” neuropsychological tests, as those measuring 
attention or working memory solely, might allow the neural system to compensate for 
diffuse complex dysfunctions in neuronal networks. On the other hand, when a test 
demands coordinated utilization among many different functions, the vulnerable patient 
might not be able to perform at an optimal level. The heterogeneity of contributing 
factors in the DST makes it difficult to determine which, of many components, have the 
larger effect on the performance 79,202,203. However, at the same time, such functional 
heterogeneity makes the test suitable to measure cognitive fatigue in different kind of 
patient groups with mild cerebral influences. For clinical purposes, this need not to be a 
problem, as broader test batteries are typically included in assessments in clinical 
settings.  
 
As self-rating instruments can be influenced by depression there is a risk of relating 
fatigue among patients to depressive disorders. Psychiatric comorbidity should be 
respected but it is unknown to what extent fatigue weights on cognitive dysfunction. In 
neuro-rehabilitation it is important to find the underlying components of different 
characteristics of fatigue, thus enabling individual rehabilitation plans to be customized. 
Thus, it is essential to develop neuropsychological tools, not subject to influence by 
depression or sleep disorder, permit both the ability to measure cognitive fatigue and to 
evaluate treatment effects 1.  
 
 
5.1.2 Cognitive fatigue in mTBI  
In this study, patients with symptoms after mTBI presented significantly more 
cognitive fatigue than did controls; which corresponded with scores higher on self-rated 
fatigue. While self-rated fatigue was correlated with self-rated depression in the patient 
group, DST-f derived cognitive fatigue was not related to depression nor to poor sleep 
quality. The lack of correlations between self-rated and cognitive fatigue is noteworthy 
and its clinical implications should be considered.  
 
The possibility to generalize the results of this study is difficult since patients with 
residual symptoms after an mTBI are a self selected group. The majority of patients 
shows full recovery 153 while many underlying reasons may account for that minority of 
patients with residual symptoms 153.  
 
Cognitive symptoms could persist in some patients due to factors such as psychiatric 
comorbidity 158. Some patients might have had a premorbid low-performing cognitive 
profile while in other cases the dysfunctions might have been primarily injury related. 
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Even though our study was a study of patients with persistent symptoms, there was 
high variability of length of time between the incident-accident and subsequent 
assessment. Theoretically, cognitive fatigue should be more prominent in patients 
assessed very soon after injury as natural recovery, at least in some degree, is expected 
150. However, in this study the sample size was too small for separate analyses to 
examine effects of latency between accident and assessment. 
 
As seen in studies included in this thesis and in other previous studies, the underlying 
cause of self-perceived fatigue could be depression or sleep disorders. Depression or 
sleep disturbances could be related to the trauma but, nonetheless, contributing factors 
such as lack of social support, financial concerns, etc. must also be considered.  
 
Our study provides support for an argument that it is important to reflect on the type of 
instruments used when assessing persisting symptoms among patients with mTBI. 
Questionnaires used during recurrent assessments run a high probability of measuring 
depression rather discriminating the true level and quality of injury-related symptoms. 
Smaller studies may be weak due to inadequate power and, with them, blinding is 
difficult in studies were neuropsychological assessment is used. Such factors could 
exclude such studies from being enrolled in meta-analyses. The minority of patients 
with residual dysfunction may be overlooked in meta-analyses 204. 
 
Furthermore, when evaluating the effects of neuropsychological impairment, 
interpretation and weighting of scores is often forgotten. In cases where 
neuropsychological instruments are used it is also of importance to bear in mind the 
everyday effect of test results. For example, impaired working memory might be much 
more problematic to cope with in the everyday setting than, say, visuospatial 
shortcomings. 
 
 
5.1.3 Effects of hormone replacement on memory and fatigue 
In Study II, the main finding was that the addition of testosterone to estrogen therapy 
carried a greater effect to impair immediate verbal memory compared to estrogen plus 
placebo treatment. This finding is contrary to a study by Sherwin in 1988, in which she 
found positive effects of testosterone treatment in oophorectomized women 167. On the 
other hand, a population-based study found a negative association between testosterone 
and verbal fluency, semantic and episodic memory in women. The influence was 
stronger with increasing age 205. It is, however, problematic to compare treatment 
studies with population-based studies since the basis for drawing conclusions are quite 
unequal for different types of studies. 
 
In Study III, no straight forward relation emerged between testosterone treatment and 
cognitive fatigue; but the study suggested that the balance between estrogen and 
testosterone levels is important. During testosterone and estrogen therapy, both 
testosterone and estrogen levels were generally high. While undergoing testosterone 
supplementation, several women in the upper quartile of the E/T ratio showed fatigue. 
In contrast, during estrogen and placebo treatment, in which estrogen levels were 
relatively high compared to testosterone levels, the women who did not reach the upper 
quartile suffered significantly more from cognitive fatigue. These results may fit a 
model with a curvilinear relationship indicating potential influence of hormone levels 
on cognition 100,206. 
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Studies regarding sex hormonal levels and cognitive performance seldom show 
conclusive results 96-99. The reasons are many, including: 
- Methods for measuring low levels of testosterone, as in women, have a large 
degree of uncertainty 207.  
- Testosterone can be aromatized to estradiol and thus testosterone treatment can 
also increase levels of serum estrogens, complicating the interpretation of the 
treatment effect 102.  
- The association between neuropsychological functions and sex steroid hormone 
levels might not be strictly dose dependent 100,101 and the balance and ratio 
between estradiol and testosterone may be an important modulator in cognitive 
function in women 120. 
- Time elapsed between oophorectomy and treatment is important - there might 
be permanent loss of estrogenic and testosteronic synapses in the human brain 
after a period of hormone depletion. Toran-Allerand et al. (1992) found that 
estrogens, along with other growth factors, were crucial for the survival of 
certain estrogen-responsive neurons. Therefore, estrogen-sensitive neurons may 
be lost with estrogen depletion; and,  
- Type of testosterone preparation with divergent dose and pharmacokinetic 
properties. Fluctuating pattern and peak levels can result in testosterone levels 
exceeding the upper limit of the established female norms 208,209.  
 
The mean time between oophorectomy and inclusion in the study exceeded 5 years and 
no information was available regarding the individual cases for data analyzes. The long 
latency between surgery and treatment could have had effects on receptor function for 
both estrogen and testosterone. Unfortunately, there was missing data on the number of 
oophorectomized women who had received HT before the study recruitment. 
Therefore, we did not examine correlations between mean time since oophorectomy 
and cognitive function. 
 
Another reason for the different results might be that tests used in our study might have 
lacked sensitivity to detect subtle differences. A more sensitive test battery is needed to 
capture more subtle aspects of memory functions.  
 
 
5.1.4 Fatigue and cognition in untreated Graves’ disease 
The patients with newly diagnosed GD gave higher self-ratings of fatigue. Fifty percent 
of these patients were found to have cognitive fatigue compared to 19 % among the 
controls. While self-rated fatigue was related to depression among the patients, 
cognitive fatigue was not.  
 
No correlation was obtained between T3 levels and cognitive fatigue. However, 
although no correlations were elicited between hormones and cognitive fatigue, high 
free T3 was positively associated with neuropsychological performance.  
The associations were, however, not in the expected direction, that is,  high T3 is 
related to severity of the disease 169. On the other hand, self-ratings of everyday 
consequences of fatigue were associated to higher T3 levels. It could be interpreted that 
patients with high free T3 levels are more hyper-vigilant due to increased metabolism, 
resulting in high activity level that produces secondary consequences of fatigue. This 
could also suggest that higher free T3 levels somehow benefit cognition in GD. Data 
are inconclusive whether high T3 levels directly benefit cognition in GD or if factors 
such as general health contribute to enhanced T3 levels.  
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Another interesting related finding was that smokers had lower levels of free T3 and 
free T4 compared to non-smokers. In studies on GD, smoking has been associated to 
poor outcome after ophthalmopathy 210,211 and menstrual disturbances 212, probably 
associated with oxidative stress 213.  
 
Neuropsychological studies on untreated patients with Grave’s disease have been 
sparse and inconsistent. Earlier studies have shown attention and memory difficulties, 
and problems with complex problem solving 178,179. Others have found no 
neuropsychological dysfunctions in GD patients 173. Findings concerning the 
relationship between hormonal levels and cognitive functions have been sparse.  
 
A limitation of this study was too small a sample size that restricted subgroup 
analyses and that hormonal data was not obtained for the controls. Another limitation 
in this study was that in order to spare the patients from a prolonged time to treatment 
the neuropsychological assessment was performed at visit while controls were tested 
over two visits.  
 
The study, nevertheless, confirms the presence of fatigue and neuropsychological 
dysfunctions among patients with untreated GD, which also could support previous 
findings regarding subjective complaints of fatigue and a decreased quality of life in 
this group 176. 
 
 
5.1.5 Cognitive fatigue as a dysfunction 
Attention, working memory and motor speed are functions vulnerable to mild or 
diffuse brain influences after mild traumatic brain injury 6,214,215, ischemic vascular 
lesions 216, sleep apnea 217 but age-related changes also contribute to alternations in 
white matter integrity 218. 
 
In both Studies I and IV the frequency of cognitive fatigue was higher in the patient 
groups compared to healthy controls; 62 % of the mTBI patients and 50 % GD 
patients showed cognitive fatigue compared to 19 % of the healthy controls, but there 
might have been different underlying mechanisms resulting in the fatigue in two 
different patient groups respectively.  
 
Medications such as beta-blockers and anti-depressant medications are associated 
with reports of fatigue 59. In Study I, no association between type of medication and 
cognitive fatigue was found. However in Study IV use of beta-blockers were less 
common in the cognitive fatigue group than in the non-fatigue group. Thus one can 
not rule out that the use of beta-blockers prior to the assessment would have had an 
impact on the results.  
 
In Study III, cognitive fatigue was quite frequently elicited within the group of 
untreated, oophorectomized women at baseline. However, no comparison with a 
control group was possible. Cognitive fatigue was related to high BMI and low self-
rated health and low self control. Women suffering from cognitive fatigue had a BMI 
corresponding to being overweight but not obese; and, according to the general health 
items in PGWB they were more likely to complain of physical disorders or pain and 
general health concerns compared to the women without fatigue at baseline. This was  
intriguing as the exclusion criteria were rigorous by not allowing cerebrovascular 
insults, smoking, and medication. On the other hand, the association between 
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cognitive fatigue and high BMI is in line with a recent study on psychomotor 
vigilance by Lee et al. 219. Obesity has also been associated with impaired health-
related quality of life and disability as measured by self rating scales 220.  
 
Neither Study III nor IV showed any direct hormonal correlation to fatigue. However in 
Study III there were indications that cognitive fatigue could be related to an imbalance 
between E/T levels. Also, in Study IV the T3 levels were associated to 
neuropsychological functions, such as working memory and psychomotor speed, 
functions that could be related to the underlying abilities demanded for performance of 
the DST. This implies that cognitive fatigue is probably not directly linked to 
hormones, rather, it is a consequence of different kinds of influence, giving rise to 
imbalance in sensitive cognitive systems. 
 
Furthermore, cognitive fatigue did not correlate to self-rated fatigue in either Study I 
or IV, while self-rated fatigue was correlated to depression among mTBI and GD 
patients. Findings of association between self-ratings and performance have been 
difficult to obtain in studies of different medical illnesses 33,221,222. This probably 
reflects that subjective fatigue is not the same as cognitive fatigue. The studies 
indicate that subjective fatigue is more related to psychological factors such as 
depression and sleep disturbance, while fatigue measured with neuropsychological 
tests is more related to cognitive functions such as attention, working memory, 
executive functions or a complex interaction of these factors. Measuring cognitive 
fatigue is thus not the same as measuring self-rated subjective fatigue. It is important 
to keep this in mind when evaluating fatigue in clinical populations as self-rated and 
cognitive fatigue brings different dimensions to the concept of fatigue. 
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6 GENERAL CONCLUSION 
As fatigue is a diffuse phenomenon with multidimensional features, it is important to 
distinguish factors that initiate fatigue from factors that perpetuate or exacerbate 
fatigue67. Self-rating instruments are influenced by e.g. depression and sleep disorders 
therefore neuropsychological tools capable of measuring cognitive fatigue are required. 
This study, consistent with earlier findings, found that cognitive fatigue could be 
detected using tests that demand simultaneous, complex cognitive functioning, such as 
attention, working memory and psychomotor functions. In particular, the Digit Symbol, 
using a scoring method that isolates a fatigue index, seems to be a valid instrument that 
can detect cognitive fatigue, despite comorbid features of depression or sleep 
disturbances. Also, again in line with previous studies, cognitive fatigue related to BMI 
and general health. Cognitive fatigue did not seem to be directly related to sex 
hormonal levels or T3 levels; rather, secondary mechanisms, such as hormonal 
imbalance could influence subtle neuronal mechanism leading to discrete 
neuropsychological dysfunctions. The lack of coherence between cognitive fatigue and 
self-perceived fatigue suggest that we measure different aspects of fatigue with 
neuropsychological tests compared to self-rating instruments.  
 
 
6.1 FUTURE STUDIES 
Although cognitive fatigue was over represented in the patient group we could not 
know the mechanisms behind the results. In an ongoing fMRI project with Arterial spin 
labeling technique on mTBI patients suffering from fatigue we will investigate if there 
are differences in neuronal resting state before, during and after a vigilance challenge. 
This might provide information about neuronal activity leading to overload under 
activity, but also on whether the fatigue patient after activation recovers neuronal 
activity more effectively than a comparative control.  
 
The interaction between BMI, hormones, general health and fatigue would certainly 
be worth while studying more. From a psychoneuroimmunological perspective 
factors such as high BMI 223, traumatic brain injury 224 neurological diseases 31 stress 
and depression have been related to inflammatory processes 225 and could 
theoretically give secondary negative effects on cognition 226. 
 
Patients suffering from GD, suffered from fatigue and demonstrated lower 
neuropsychological performance on several tests. The neuropsychological field is 
open for interesting studies as this is not yet neuropsychologically thoroughly studied. 
Prior research indicated that some patients do not feel fully recovered after treatment 
despite having regained normal hormonal levels 176,177. Questionnaires as well as 
neuropsychological tests should be employed in studies on treatment recovery. 
Furthermore we still have insufficient knowledge about the long-term effects on 
cognition due to prolonged imbalance in hormone levels in humans. 
 
Fatigue is one of the most difficult symptoms to cope with as well as to ascertain and 
relieve. It deeply impacts social and physical functioning, and it is, therefore, highly 
important to learn methods to assess different aspects of fatigue, and to find proper 
treatments. In this thesis, we found that cognitive fatigue was best captured using 
tasks that demand complex functioning and we also found different factors associated 
to performance decrements. Adopting a multi-professional approach is important 
when investigating fatigue, as well as when finding ways to treat it. 
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7 SAMMANFATTNING PÅ SVENSKA 
Trötthet drabbar många patienter efter sjukdomar som påverkar hjärnan men också vid 
hormonförändringar. Trots att trötthet har intresserat psykologer sedan den moderna 
psykologins begynnelse saknas det fortfarande en enhetlig definition av begreppet och 
bra mätmetoder. Trötthet påverkar livskvalitet och arbetsliv och är ett av de vanligaste 
orsakerna till att sjukskrivna personer inte lyckas komma tillbaka i arbete. 
  
Den självupplevda tröttheten mäts med skattningsskalor. Problemet med att mäta ett 
symptom med enbart skattningsskalor är att svaren i många fall är förknippade med 
andra tillstånd som påverkar resultatet då t.ex. deprimerade personer har en benägenhet 
att skatta mera besvär på skattningsskalor. 
 
För att kunna rehabilitera och behandla patienter optimalt är det viktigt att kunna 
särskilja trötthet som beror på underliggande neuropsykologiska funktionsnedsättningar 
från trötthet som är sekundär till följd av depression eller sömnstörningar. Det finns 
därför ett behov att utveckla instrument som är kliniskt lättanvända och kan skilja 
funktionsnivå från självupplevda symptom.  
 
Vi har studerat olika neuropsykologiska metoder som kan vara lämpliga för att fånga 
kognitiv trötthet och att undersöka om specifika hormonförändringar och behandlingar 
bidrar till kognitiv trötthet. 
 
Tre olika patientgrupper ingick i studien; Patienter som drabbats av en lätt traumatisk 
hjärnskada, kvinnor som opererat bort äggstockar och som utöver behandling med 
östrogen erhöll tilläggsbehandling med testosteron, patienter med nydiagnostiserad men 
obehandlad Graves sjukdom (giftstruma).  
 
Avhandlingen har kunnat visa att kognitiv trötthet, i enlighet med tidigare forskning, är 
mer framträdande på test som kräver uppmärksamhet, arbetsminne och motoriska 
funktioner och där man samtidigt måste bearbeta komplex information. Deltestet 
Kodning från Wechslerskalorna verkar vara ett test som har lämpliga egenskaper för att 
mäta kognitiv trötthet hos patienter med lätta traumatiska hjärnskador. Självskattad 
trötthet verkar vara mera relaterad till nedstämdhet och sömnstörningar medan så inte 
är fallet för kognitiv trötthet. 
 
Hos obehandlade kvinnor som opererat bort äggstockar var könshormonnivåerna 
generellt mycket låga och man fann inget samband mellan hormonnivåer och trötthet. 
Tröttheten var kopplad till övervikt och sämre självskattad hälsa. När dessa kvinnor 
behandlades med antingen östrogen och placebo (sockerpiller) eller östrogen och 
testosteron visade det sig att det inte var hormonnivåerna i sig som var relaterade till 
kognitiv trötthet utan snarare tycktes förhållandet mellan östrogen- och 
testosteronhalten vara viktigare. Man fann också att testosteronbehandling som tillägg 
till östrogenbehandling hade en negativ effekt på vissa minnesfunktioner. 
 
Patienter med Graves sjukdom upplevde högre grad av självskattad trötthet och hälften 
av patienterna led av kognitiv trötthet jämfört med endast en femtedel av deltagarna i 
kontrollgruppen. De presterade också sämre på tester för motorik, inlärning och minne. 
De hade svårare att generera ord och sämre språkligt arbetsminne. De som hade höga 
nivåer av tyroideahormonet trijodtyronin (T3) fungerade bättre vad gäller 
bearbetningshastighet, uppmärksamhet och vissa minnesfunktioner och hade även 
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bättre impulskontroll men de upplevde större problem med självskattade 
vardagskonsekvenser av trötthet. Rökare hade generellt lägre nivåer av fritt T3 än icke-
rökare.  
 
Sammantaget talar studierna för att det är möjligt att mäta kognitiv trötthet med test 
som kräver samtidig bearbetning av komplexa kognitiva funktioner. Deltestet Kodning 
från Wechslerskalorna har egenskaper som är lämpliga för att mäta kognitiv trötthet då 
depression och sömnstörningar inte påverkade resultatet. Kognitiv trötthet verkar vara 
relaterat till BMI och självrapporterad hälsa men inte direkt till hormonnivåer. Däremot 
är det möjligt att sekundära mekanismer såsom hormonell obalans kan påverka känsliga 
neuronala processer och därmed leda till diskreta neuropsykologiska dysfunktioner.  
 
Bristen på samstämmighet mellan självskattad trötthet och kognitiv trötthet kan bero på 
att vi mäter olika aspekter av trötthet när vi använder frågeformulär jämfört med 
neuropsykologiska test. 
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10 APPENDICIES 
10.1 MOTORISK SCREENING FRÅN LURIABATTERIET 
 
 
 
 
Föreligger perifer nervskada?     Nej  Ja                 Var?_________________________ 
 
 
D1. Händernas motoriska funktion  
D1.1 Enkel rörelse 
 
 D.1.1.1 Gör som jag.  Börja med dominant hand och sätt tummen mot pek, lång, ring 
             och lillfingrarna i tur och ordning. Gör så snabbt du kan!  
             Pat får göra så 5 gånger med dominant hand. 
 
Markera misslyckade försök med kryss: 
      
        summa korrekt domin:___ 
 
  Gör nu samma sak med den andra handen!  
Markera misslyckade försök med kryss:     
    
         summa korrekt i-dom:___ 
 
  
 D1.1.2      Gör som jag: Lägg händerna på bordet med handflatan nedåt. Spreta ut  
                 med fingrarna och för ihop dem. Använd båda händerna och forstätt till 
                 jag säger till: Pat får göra så fem gånger: 
 
Markera misslyckade försök med kryss:    
 
                                                               summa korrekt bilateralt:___ 
 
Noteras lateralisering mellan höger / vänster? __________________________________________ 
 
 
 
D.1. 2 Rörelsens kinestetiska bas    
  D.1.2.2 Churchill – Manson testet: 
   Placera dominant hand på bordet (täck över med blocket så att pat inte  
   ser) och gör likadant som jag gör (gör Churchill tecken) och gör sedan  
   Manson tecknet om pat klarar uppgiften. 
   Klarar pat båda uppgifterna?       Ja:   Nej:   
   Om ja (2 poäng/rörelse): max 4 poäng  
 
   Om nej: klarar pat då han/hon ser fingrarna Ja:    Nej:    
   Om ja: 1 poäng/rörelse: max 2 poäng 
                 summa dominant:___ 
 
  Gör samma sak nu med den icke-dominanta handen: 
 
   Klarar pat båda uppgifterna?  Ja: Nej:    
   Om ja (2 poäng/rörelse): max 4 poäng  
 
   Om nej: klarar pat då han/hon ser fingrarna     Ja:    Nej:    
   Om ja: 1 poäng/rörelse: max 2 poäng 
                  summa icke-dom:___ 
Datum:              Luria – motorisk dynamik        Namn:   
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  D.1.4 Rörelsens dynamiska organisation 
 
 D1.4.1.1 Lägg händerna som jag och låt dem växla ställning samtidigt (fig. 4). 
  Låt pat växla 10 ggr: 
 
Markera misslyckade försök med kryss:          
          
  
       summa korrekt:____ 
  
   D.1.4.2 Lägg händerna på bordet och knacka två gånger med dominant hand  
    och en gång med icke-dominant hand. När pat lärt sig be pat byta till  
    icke- dominant hand (två med icke-dominant hand och en med dominant 
    hand). Be sedan pat växla lugnt från ena sidan till den andra med ojämna  
    mellanrum när du säger byt.  
   Pat får göra 7 växlingar. 
 
Markera misslyckade försök med kryss:        
 
                summa korrekt:____ 
 
 
 
  D.1.4.4  Inta de här ställningarna med dominant hand (fig. 7). Säg samtidigt  
              ”knytnäve, sida, handflata”. Låt pat göra rörelsen 5 ggr med dominant  
   hand efter några gångers övning tillsammans med tl: 
 
Markera misslyckade försök med kryss:    
 
     summa korrekt domin:____ 
 
 
   Gör nu samma sak med icke-dominant hand: 
 
Markera misslyckade försök med kryss:   
  
             summa korrekt i-dom:____ 
 
 
D.3.2.3.1 Konfliktreaktioner 
 
  Om jag sträcker fram mitt finger ska du visa din knutna hand 
  och om jag sträcker fram min knutna hand ska du visa ditt finger. 
    
 
Markera misslyckade försök med kryss: 
 
    F      KH     KH       F       F       KH      F      KH      F       KH    
          
 
       summa:_____ 
 
 
    Total summa samtliga uppgifter:      /60 
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10.2 VARDAGSKONSEKVENSER AV TRÖTTHET 
 
 
Följande frågor gäller din upplevelse av trötthet den senaste månaden. 
Dina svar gäller det mest riktiga svaret för flesta av dagar under senaste månaden. 
Var snäll och besvara alla frågor. 
 
 
Hur ofta har tröttheten gjort att Du  ... 
 
(a) somnat dagtid eller tidig kvällstid under fysisk inaktivitet (t.ex. vid teven eller på 
möte)? 
 
Inte under den   Mindre än  En eller två   Minst tre 
senaste månaden ____ en gång i veckan ____ gånger i veckan ____ gånger i veckan ____ 
 
 
(b) varit tvungen att sova middag? 
 
Inte under den   Mindre än  En eller två   Minst tre 
senaste månaden ____ en gång i veckan ____ gånger i veckan ____  gånger i veckan ____ 
 
 
(c) gäspat flera gånger under dagen? 
 
Inte under den   Mindre än  En eller två  Minst tre 
senaste månaden ____ en gång i veckan ____ gånger i veckan ____ gånger i veckan ____ 
 
 
(d) avstått att göra uppgifter som är tankekrävande? 
 
Inte under den   Mindre än   En eller två  Minst tre 
senaste månaden ____ en gång i veckan ____  gånger i veckan ____  ånger i veckan ____ 
 
 
(e) avstått från fysiskt krävande uppgifter? 
 
 
Inte under den    Mindre än   En eller två  Minst tre 
senaste månaden ____ en gång i veckan ____gånger i veckan ____   gånger i veckan____ 
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10.3 FRÅGEFORMULÄR OM MINNET 
 
Namn:___________________ 
 
Datum:___________________ 
 
 
INSTRUKTION: Kryssa för det alternativet som bäst motsvarar Ditt sätt att vara under 
den senaste månaden. 
 
 
  Stämmer     Stämmer Stämmer Stämmer     
   inte alls   ibland   ofta   helt    
 
 
 
1. Mitt minne är inte vad det varit. 
 
2. Jag glömmer uträtta det jag har planerat 
 
3. Jag kommer ihåg att lämna meddelanden 
 till andra. 
 
4. Jag glömmer var jag lagt viktiga saker. 
 
5. Jag glömmer vad man har sagt mig 
 någon dag tidigare. 
 
6. Jag påbörjar något och glömmer 
 sedan vad det var jag ville göra. 
 
7. Jag har lätt för nya rutiner. 
 
8. Jag glömmer lätt folks namn. 
 
9. Jag har svårt att samla tankarna. 
 
 
 
TACK FÖR DIN MEDVERKAN  
 
 
 
 
 
 
 
 
 
 
